BioCentury
ARTICLE | Clinical News

Civacir: Phase III started

August 19, 2013 7:00 AM UTC

Biotest began the open-label, North American Phase III Study 988 to evaluate 200 and 300 mg/kg Civacir in up to 90 patients. Patients will receive Civacir starting on the day of liver transplant, but prior to the transplant, followed by 15 infusions over 10 weeks plus standard immunosuppressant therapy. Civacir has Orphan Drug designation in the U.S. and EU to prevent HCV infection in liver transplant patients. ...